OH-LUBRIZOL
18.1.2024 15:18:27 CET | Business Wire | Press release
Lubrizol Advanced Materials announces that three additional Lubrizol Engineered Polymers sites obtained the International Sustainability and Carbon Certification (ISCC) PLUS certification at the end of last year.
ISCC PLUS is an international sustainability certification for industrial applications, a standard for fully traceable sustainable supply chains that allows companies to track and attribute environmentally friendly raw materials along the entire value chain, through transparent record-keeping and without altering the production process.
The three sites that have achieved this highly valued third-party qualification, the ISCC PLUS certification, are Lubrizol Advanced Materials’ headquarters in Brecksville and the production plants in Avon Lake, Ohio, U.S., and Oevel, Belgium.
As part of Lubrizol’s commitment to sustainability, and our expansion of ESTANE® TPU sustainable solutions, these certifications follow last year’s ISCC PLUS certification of Lubrizol’s facility in Songjiang, China. Our sustainable solutions can be used in different industries, including footwear, electronics, and industrial applications.
“ISCC PLUS enables a fully transparent biomass balance approach and leads to the decrease of the Product Carbon Footprint (PCF) of our final product. This builds up on the launch of our ESTANE RNW TPU solutions which reduces the PCF with the existing equipment used by our customers, without any change in the production process or final material properties,” said Dr. Jesús Santamaria, Global Sustainability Business Director for Lubrizol Engineered Polymers.
“Obtaining ISCC PLUS certification is an important step in ensuring that Lubrizol has a single, consistent, corporate-wide process across our organization to track materials. As we increase our use of bio-based* and renewable materials, Lubrizol’s customers are provided even more confidence in our ability to credibly trace these materials through our manufacturing process,” said Elizabeth Grove, Chief Sustainable Officer, The Lubrizol Corporation.
Expanding the use of alternative feedstocks using the mass balance approach whilst adopting this ISCC PLUS external verification system as an essential tracking element, will support the acceleration of Lubrizol’s global sustainability journey. We are collaborating with our partners and building alliances to develop solutions that bring positive impacts to the environment and society, which outweigh the footprint it takes to produce them.
About Lubrizol
The Lubrizol Corporation, a Berkshire Hathaway company, leverages its unmatched science and innovation to solve complex challenges for customers, drive sustainable and measurable results and help millions of people, communities and businesses around the world move cleaner, create smarter and live better every day. Founded in 1928, Lubrizol operates more than 100 manufacturing facilities, sales and technical offices around the world and has approximately 8,000 employees. For more information, visit www.Lubrizol.com.
ISCC PLUS Certification of three of Lubrizol Engineered Polymers sites help drive the global expansion of ESTANE® TPU sustainable solutions.
*Bio-based content as determined according to ASTM D6866
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240118948548/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom